Skip to main content

Table 11 Costs avoided by age group

From: Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children

Influenza-associated costsAge group
0–4 years5–11 years12–49 years50–59 years≥60 years
Direct costs
 Laboratory diagnosis1,705,2705,970,1342,729,7971,060,3931,805,053
 Medical consultations1,537,7007,238,9553,285,4581,040,0381,476,373
 Drugs200,4471,403,033638,823177,367170,223
 Hospitalisations12,948,38340,807,24218,282,3687,697,33013,775,872
 Influenza immunisation to school-aged population −27,421,602   
Total direct costs avoided (third-party payer perspective)16,391,79927,997,76324,936,4469,975,12817,227,521
Indirect costs
 Productivity loss2,243,9277,026,8663,186,5881,357,530616,517
 Premature death16,215137,958526,445229,548119,216
 Total indirect costs avoided2,260,1427,164,8243,713,0331,587,079735,733
Total costs of influenza avoided (societal perspective)18,651,94135,162,58628,649,47911,562,20617,963,254
  1. All costs are in USD